Dr.Lal PathLabs Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 5,800,000 (50%) | — | ₹31,900 Cr |
| NII (HNI) | — | 1,740,000 (15%) | — | ₹9,570 Cr |
| Retail | — | 4,060,000 (35%) | — | ₹22,330 Cr |
| Σ Total | — | 11,600,000 (100%) | — | ₹638,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹11,000 |
| Retail (Max) | 13 | 260 | ₹143,000 |
| S-HNI (Min) | 14 | 280 | ₹154,000 |
| B-HNI (Min) | 67 | 1,340 | ₹737,000 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Mar 15 | 31 Mar 14 | 31 Mar 13 |
|---|---|---|---|
| Revenue | 640 | 544 | 424 |
| Profit After Tax | 88 | 74 | 49 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 To achieve the benefits of listing the Equity Shares on the Stock Exchanges –
Company Overview
Dr. Lal PathLabs Limited is a Delhi based provider of diagnostic and related healthcare tests and services in India. Through its nationwide network, company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Company has built a national network consisting of its National Reference Laboratory in New Delhi, 163 other clinical laboratories, 1,340 patient service centers and over 5,000 pickup points as of March 31, 2015.
Company's customers include individual patients, hospitals and other healthcare providers and corporate customers.
Highlights:
1. Company offers 3,368 diagnostic and related healthcare tests.
2. Company collected 21.8 million samples from 9.9 million patients in FY 2015.
3. Company is well-positioned to leverage upon one of the fastest-growing segments of the Indian healthcare industry.
4. Its centralized information technology platform fully integrates to it network and is scalable.